327 related articles for article (PubMed ID: 36655304)
1. The role of different viral biomarkers on the management of chronic hepatitis B.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):263-276. PubMed ID: 36655304
[TBL] [Abstract][Full Text] [Related]
2. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
Wu JW; Kao JH; Tseng TC
Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
[TBL] [Abstract][Full Text] [Related]
3. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
Cornberg M; Lok AS; Terrault NA; Zoulim F;
J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
[TBL] [Abstract][Full Text] [Related]
6. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
7. What will it take to cure hepatitis B?
Jeng WJ; Lok ASF
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
[TBL] [Abstract][Full Text] [Related]
9. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
[TBL] [Abstract][Full Text] [Related]
10. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong GLH; Gane E; Lok ASF
J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
12. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
[TBL] [Abstract][Full Text] [Related]
13. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
[TBL] [Abstract][Full Text] [Related]
14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
15. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
[TBL] [Abstract][Full Text] [Related]
16. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy.
Wu CJ; Chau GY; Lee IC; Huo TI; Su CW; Hou MC; Huang YH
J Formos Med Assoc; 2021 Aug; 120(8):1563-1571. PubMed ID: 33334659
[TBL] [Abstract][Full Text] [Related]
17. How to interpret viral markers in the management of chronic hepatitis B infection.
Riveiro-Barciela M; Pericàs JM; Buti M
Clin Microbiol Infect; 2022 Mar; 28(3):355-361. PubMed ID: 34768018
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
19. Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
Buti M; Riveiro-Barciela M; Rodríguez-Frías F; Tabernero D; Esteban R
Semin Liver Dis; 2020 Feb; 40(1):49-60. PubMed ID: 31805583
[TBL] [Abstract][Full Text] [Related]
20. Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
Lee JH; Lee YB; Cho EJ; Yu SJ; Yoon JH; Kim YJ
Clin Infect Dis; 2021 Nov; 73(9):e3308-e3316. PubMed ID: 32556157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
